BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

BeiGene Ltd.

Nomura analyst maintained a Buy rating on BeOne Medicines Ltd on July 24 and set a price target of HK$270.74. The company’s shares closed yesterday...

BeOne Medicines Ltd (6160) Gets a Buy from Nomura

Oncolytics Biotech ( ($ONCY) ) has issued an update. On July 20, 2026, Oncolytics Biotech disclosed that it received a notice from Nasdaq indicatin...

Oncolytics Biotech Faces Nasdaq Minimum Bid Price Noncompliance

RBC Capital analyst Piral Dadhania maintained a Hold rating on Moncler S.p.A. on July 22 and set a price target of €59.00. The company’s shares clo...

Moncler S.p.A. (0QII) Gets a Hold from RBC Capital

In a report released today, Carole Madjo from Barclays maintained a Buy rating on Moncler S.p.A., with a price target of €62.00. According to TipRa...

Barclays Remains a Buy on Moncler S.p.A. (0QII)

The latest update is out from Oncolytics Biotech ( ($ONCY) ). On July 20, 2026, Oncolytics Biotech announced that the U.S. Food and Drug Administra...

Oncolytics Biotech gains FDA Fast Track for pelareorep

Macquarie analyst maintained a Buy rating on BeOne Medicines Ltd on July 13 and set a price target of HK$257.00. The company’s shares closed yester...

BeOne Medicines Ltd (6160) Receives a Buy from Macquarie

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1/1b study titled “A Phase 1/1b Open-Label Dose-Escalation an...

BeOne Medicines Halts Early BGB-21447 Cancer Trial: What Investors Should Watch

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Olema Pharmaceutical...

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Olema Pharmaceuticals (OLMA)

Oncolytics Biotech ( ($ONCY) ) has provided an announcement. On July 13, 2026, Oncolytics Biotech reported clinical and regulatory progress for its...

Oncolytics Biotech advances REO 033 colorectal cancer program

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Stoke Therapeutics (STOK) and Oncolytics Biotech (ON...

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Oncolytics Biotech (ONCY)

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ticker: ONC) is running a Phase 2 study in the U.S. to...

BeOne Medicines Advances Minority-Focused Cancer Trial With Tislelizumab Combo

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines is running a Phase 1 study in healthy adults to test ho...

BeOne Medicines Advances Sonrotoclax Formulation Study, Signaling Progress in ONC Pipeline

BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines is running an early study called “A Phase 1a/1b Study E...

BeOne Medicines Steps Up in Myeloid Cancer With New BG-75202 Trial

In a report released yesterday, from Huafu Securities maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$297.44. The word on...

Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

RBC Capital analyst Piral Dadhania maintained a Hold rating on Moncler S.p.A. yesterday and set a price target of €59.00. According to TipRanks, Da...

Moncler S.p.A. (0QII) Receives a Hold from RBC Capital

In a report released on July 1, from UBS maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$273.60. BeOne Medicines Ltd has ...

UBS Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) a...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), BeOne Medicines (ONC) and Zevra Therapeutics (ZVRA)

The latest update is out from Oncopeptides AB ( ($SE:ONCO) ). Oncopeptides AB has adjusted its share structure following the conversion of 209,640 ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ONC	$325.90	0.00%	302.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ONC	$325.90	0%	302.47K
3
4
5
6

ONC

ONC

Get BeiGene Ltd. Data in Excel

Get BeiGene Ltd. Data in Excel